Treatment with the semi-synthetic FXR agonist, obeticholic acid, over 72 weeks only achieved a modest reduction in body weight (~2 kg) in patients with non-alcoholic fatty liver disease (NAFLD), with or without, T2D [60]. The gene discussed is NR1H4; the disease is type 2 diabetes mellitus.